Approval from Health Canada -

Code BSE: 532321 NSE:

Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg Liothyronine tablets, a synthetic form of the thyroid hormone T3 (triiodothyronine), are primarily indicated for treating hypothyroidism. ZDS- Liothyronine tablets will be manufactured at Zydus’ plant in Ahmedabad SEZ. Liothyronine tablets had annual sales of 10.9 mn CAD (Canadian Dollars) in Canada (IQVIA MAT June 2025)